Dr. Adam Levy has served as Acrivon's Chief Financial Officer since April 2025, having joined in July 2023 as Senior Vice President and Head of Corporate Affairs and Investor Relations. Before Acrivon he was Senior Vice President of Investor Relations at Zentalis Pharmaceuticals and SVP of Investor Relations and Corporate Communications at Turning Point Therapeutics, where he was part of the team that delivered the company's $4.1 billion acquisition by Bristol Myers Squibb. Earlier he held corporate-strategy and corporate-development roles at Alaunos Therapeutics, Gilead Sciences, Pfizer, Novartis and Alexion, and was an engagement manager at McKinsey & Company. Dr. Levy received an M.B.A. from the Kellogg School of Management at Northwestern University, a Ph.D. in molecular biology from the University of Illinois at Chicago and a B.S. in genetics from the University of Illinois at Urbana-Champaign.